|
1
|
Sethi A, Tandon A, Mishra H and Singh I:
Diffuse large B-cell lymphoma: An immunohistochemical approach to
diagnosis. J Oral Maxillofac Pathol. 23:284–288. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Reksodiputro AH: Multicenter epidemiology
and survival study of B cell non Hodgkin lymphoma patients in
Indonesia. J Blood Disorders Transf. 6(257)2015.
|
|
3
|
Rosenwald A, Wright G, Chan WC, Connors
JM, Campo E, Firsher RI, Gascoyne RD, Muller-Hermenlink K, Smeland
EB, Giltnane JM, et al: The use of molecular profiling to predict
survival after chemotherapy for diffuse large-B-cell lymphoma. N
Engl J Med. 346:1937–1947. 2002.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Jiang X, Wang J, Deng X, Xiong F, Ge J,
Xiang B, Wu X, Ma J, Zhou M, Li X, et al: Role of the tumor
microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol
Cancer. 18(10)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nishimura H, Agata Y, Kawasaki A, Sato M,
Imamura S, Minato N, Yagita H, Nakano T and Honjo T:
Developmentally regulated expression of the PD-1 protein on the
surface of double-negative (CD4-CD8-) thymocytes. Int Immunol.
8:773–780. 1996.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Xia Y, Jeffrey Medeiros L and Young KH:
Signaling pathway and dysregulation of PD1 and its ligands in
lymphoid malignancies. Biochim Biophys Acta. 1865:58–71.
2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ferrata M, Schad A, Zimmer S, Musholt TJ,
Bahr K, Kuenzel J, Becker S, Springer E, Roth W, Weber MM and
Fottner C: PD-L1 expression and immune cell infiltration in
gastroenteropancreatic (GEP) and Non-GEP neuroendocrine neoplasms
with high proliferative activity. Front Oncol.
9(343)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen J, Jiang CC, Jin L and Zhang XD:
Regulation of PD-L1: A novel role of pro-survival signalling in
cancer. Ann Oncol. 27:409–416. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Alsaab HO, Sau S, Alzhrani R, Tatiparti K,
Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling
inhibition for Cancer immunotherapy: Mechanism, combinations and
clinical outcome. Front Pharmacol. 8(561)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kiyasu J, Miyoshi H, Hirata A, Arakawa F,
Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, et al:
Expression of programmed cell death ligand 1 is associated with
poor overall survival in patients with diffuse large B-cell
lymphoma. Blood. 126:2193–2201. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hu LY, Xu XL, Rao HL, Chen J, Lai RC,
Huang HQ, Jiang WQ, Lin TY, Xia ZJ and Cai QQ: Expression and
clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse
large B cell lymphoma: A retrospective study. Chin J Cancer.
36(94)2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik
JH, Kim YA, Kim TM, Heo DS, Kim CW and Jeon YK: Clinicopathological
analysis of programmed cell death 1 and programmed cell death
ligand 1 expression in the tumor microenvironments of diffuse large
B cell lymphomas. Histopathology. 68:1079–1089. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Xie M, Huang X, Ye X and Qian W:
Prognostic and clinicopathological significance of PD-1/PD-L1
expression in the tumor microenvironment and neoplastic cells for
lymphoma. Int Immunopharmacol. 77(105999)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shi Y, Han Y, Yang J, Liu P, He X, Zhang
C, Zhou S, Zhou L, Qin Y, Song Y, et al: Clinical features and
outcomes of diffuse large B-cell lymphoma based on nodal or
extranodal primary sites of origin: Analysis of 1,085 WHO
classified cases in a single institution in China. Chin J Cancer
Res. 31:152–161. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fang X, Xiu B, Yang Z, Qiu W, Zhang L,
Zhang S, Wu Y, Zhu X, Chen X, Xie S, et al: The expression and
clinical relevance of PD-1, PD-L1 and TP63 in patients with diffuse
large B-cell lymphoma. Medicine (Baltimore).
96(e6398)2017.PubMed/NCBI View Article : Google Scholar
|
